Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Vascular contributions

Topic: Risk, prevention and care in population studies

Plain-language summary

Cerebral small vessel disease is a condition caused by chronic cerebral hypoperfusion due to microvascular damage and is a major contributor to stroke and dementia. Traditionally, its diagnosis has relied primarily on neuroimaging findings. However, recent advances in the understanding of cerebral small vessel disease pathophysiology have opened new avenues for early detection and targeted therapeutic interventions. Notably, the identification and investigation of cerebral small vessel disease-related biomarkers have emerged as a promising strategy for early diagnosis. This review provides an overview of recent research on cerebral small vessel disease biomarkers, including plasma biomarkers, cerebrospinal fluid biomarkers, and genetic markers. Finally, we discuss future directions and trends in the clinical validation of these biomarkers.

What this study adds

Evidence grade: Low

This review discusses plasma, cerebrospinal fluid, and genetic biomarkers for cerebral small vessel disease as promising for early diagnosis. It does not report any treatment, cure, or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Luo, W., Cao, C., Li, W., Wei, T., Zhao, Z., Wang, G., et al. (2025). Biomarker advancements in cerebral small vessel disease: An overview. Neural Regeneration Research. https://doi.org/10.4103/nrr.nrr-d-24-01329

Vancouver

Luo W, Cao C, Li W, Wei T, Zhao Z, Wang G, et al. Biomarker advancements in cerebral small vessel disease: An overview. Neural Regeneration Research. 2025. doi:10.4103/nrr.nrr-d-24-01329. PMID: 40364622.

BibTeX

@article{luo2025-40364622,
  author  = {Luo, Wenqian and Cao, Chenhui and Li, Wenli and Wei, Ting and Zhao, Zeyu and Wang, Guanqing and Li, Xiaoli and Li, Yanbin and others},
  title   = {{Biomarker advancements in cerebral small vessel disease: An overview}},
  journal = {Neural Regeneration Research},
  year    = {2025},
  doi     = {10.4103/nrr.nrr-d-24-01329},
  pmid    = {40364622},
  url     = {https://doi.org/10.4103/nrr.nrr-d-24-01329}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses plasma, cerebrospinal fluid, and genetic biomarkers for cerebral small vessel disease as promising for early diagnosis. It does not report any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 31/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 30 of the 96 points it could be judged on, which is 31 of 100. Total 31 of 100.30 of the 96 points we could judge = 31 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 30 of the 96 points we could judge it on, which is 31 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neural Regeneration Research)
Journal's citation record 1 / 4 Neural Regeneration Research: journal h-index 100 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 0 / 3 Shandong First Medical University: institution h-index 257 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40364622)
Free to read 2 / 2 Free to read
Points 30 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 96 points we could judge it on is 31 out of 100.
Total 31 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Vascular contributions from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Vascular contributions

See all studies in Vascular contributions →